Is Oruka Therapeutics, Inc. a good investment? Oruka Therapeutics, Inc. (ORKA) is currently trading at 85.21 USD. Market analysts have a consensus price target of 142.17 USD. This suggests a potential upside from current levels.
Earnings Schedule: Oruka Therapeutics, Inc. is expected to release its next earnings report on Aug. 10, 2026. The market consensus estimate for Forward EPS is -2.46.
No, it does not currently pay a dividend.
Oruka Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Aug. 10, 2026. The company currently has a trailing EPS of -1.93.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
| Year | Total Dividends |
|---|---|
| ▸2024 |
20.97 USD
|
| Aug. 29, 2024 | 1.6130 |
| Aug. 29, 2024 | 19.3560 |
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 23, 2004 | 0.333333 |
| Jan. 28, 2009 | 0.050000 |
| March 5, 2013 | 0.166667 |
| Sept. 4, 2015 | 0.142857 |
| April 4, 2019 | 0.055556 |
| Sept. 3, 2024 | 0.083333 |
| Sept. 3, 2024 | 0.080000 |
| April 4, 2019 | 0.060000 |
| Sept. 4, 2015 | 0.140000 |
| March 5, 2013 | 0.170000 |
| Feb. 23, 2004 | 0.330000 |
Community Discussion